Share Price and Basic Stock Data
Last Updated: December 17, 2025, 9:55 pm
| PEG Ratio | 5.05 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Pfizer Ltd, a prominent player in the Indian pharmaceuticals sector, has seen its revenue trajectory reflect both resilience and volatility over recent years. For the fiscal year ending March 2025, the company reported sales of ₹2,281 Cr, a slight uptick from ₹2,193 Cr in the previous year. However, the journey to this figure has not been linear. Quarterly sales peaked at ₹637 Cr in September 2022 but have since fluctuated, declining to ₹531 Cr in June 2023 before rebounding to ₹575 Cr by September 2023. This inconsistency may indicate challenges in market demand or competitive pressures, reflecting the broader industry dynamics. Notably, the trailing twelve months (TTM) revenue has stabilized at ₹2,322 Cr, suggesting a potential floor that investors might find reassuring amidst the fluctuations.
Profitability and Efficiency Metrics
Profitability metrics for Pfizer Ltd exhibit a mixed but generally positive picture. The company recorded a net profit of ₹768 Cr for the fiscal year 2025, up from ₹551 Cr the previous year, showcasing a robust growth trajectory despite the revenue uncertainties. The operating profit margin (OPM) stood at 33.64%, a commendable figure that reflects effective cost management and operational efficiency. However, the OPM has seen fluctuations, dropping to 21% in June 2023, which raises questions about the sustainability of profit margins amid rising costs. Efficiency ratios also tell an intriguing story; the return on equity (ROE) was reported at 18.20%, indicating a strong return on shareholder funds, while the return on capital employed (ROCE) remained healthy at 19.61%. These figures suggest that while profitability remains strong, the company faces challenges in maintaining consistent operational efficiency.
Balance Sheet Strength and Financial Ratios
Pfizer Ltd maintains a robust balance sheet, characterized by minimal borrowings and healthy reserves. As of March 2025, total borrowings were a mere ₹43 Cr, which is negligible compared to the reserves of ₹4,172 Cr. This low debt level results in an impressive interest coverage ratio of 108.50x, underscoring the company’s ability to meet interest obligations comfortably. The current ratio stands at 6.17, indicating excellent liquidity, which provides a cushion against unforeseen financial pressures. Moreover, the price-to-book value (P/BV) ratio of 4.34x suggests that the stock is trading at a premium relative to its book value, reflecting market confidence in Pfizer’s growth prospects. However, investors should be cautious about the declining trend in the cash conversion cycle, which rose to 177 days. This might signal potential inefficiencies in converting sales into cash, which could impact liquidity if not addressed.
Shareholding Pattern and Investor Confidence
The shareholding structure of Pfizer Ltd reveals a stable yet concentrated ownership pattern. Promoters hold a significant 63.92% stake, indicating strong control over the company, which can be a double-edged sword. While it suggests confidence from the promoters, it may also limit the influence of minority shareholders. Institutional investors, including foreign institutional investors (FIIs) and domestic institutional investors (DIIs), hold a combined 19.71%, which reflects a moderate level of institutional interest. Notably, DIIs have been gradually increasing their stake, reaching 17.11%, which could be interpreted as growing confidence in the company’s long-term prospects. However, the public shareholding has seen a decline, dropping to 16.37%, which could indicate a waning interest among retail investors, potentially influenced by market volatility and performance inconsistencies.
Outlook, Risks, and Final Insight
Looking ahead, Pfizer Ltd presents a mixed bag for investors. On one hand, its strong balance sheet and profitability metrics suggest resilience, while the growth in institutional holdings signals a vote of confidence in its future. However, the volatility in revenue and profit margins raises concerns about operational stability, particularly in a competitive pharmaceutical landscape. Investors should also be mindful of potential risks such as regulatory changes, market competition, and fluctuating demand for its products. While the company appears to have a solid foundation, the ability to maintain profitability amidst these challenges will be crucial. Investors might consider a watchful approach, weighing the company’s strengths against its vulnerabilities, and remain alert to how management addresses operational efficiency and market dynamics in the coming quarters.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 143 Cr. | 114 | 235/84.3 | 31.7 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.38 Cr. | 1.77 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,240 Cr. | 389 | 479/192 | 87.8 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 31.8 Cr. | 42.9 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 46.9 Cr. | 32.0 | 32.0/17.0 | 112 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,299.53 Cr | 1,144.52 | 51.48 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 593 | 637 | 622 | 573 | 531 | 575 | 540 | 547 | 563 | 589 | 538 | 592 | 603 |
| Expenses | 401 | 406 | 418 | 391 | 421 | 393 | 387 | 357 | 385 | 399 | 392 | 364 | 393 |
| Operating Profit | 192 | 232 | 203 | 182 | 111 | 183 | 153 | 189 | 177 | 189 | 146 | 228 | 210 |
| OPM % | 32% | 36% | 33% | 32% | 21% | 32% | 28% | 35% | 32% | 32% | 27% | 38% | 35% |
| Other Income | -118 | 213 | 27 | 12 | 33 | 36 | 44 | 75 | 42 | 43 | 43 | 217 | 67 |
| Interest | 4 | 3 | 4 | 3 | 3 | 3 | 3 | 7 | 2 | 2 | 2 | 3 | 3 |
| Depreciation | 27 | 26 | 26 | 26 | 16 | 15 | 18 | 14 | 15 | 15 | 15 | 16 | 14 |
| Profit before tax | 43 | 415 | 201 | 165 | 126 | 201 | 176 | 244 | 203 | 215 | 172 | 426 | 260 |
| Tax % | 25% | 25% | 25% | 21% | 26% | 26% | 26% | 27% | 26% | 26% | 26% | 22% | 26% |
| Net Profit | 33 | 311 | 151 | 130 | 94 | 149 | 130 | 179 | 151 | 158 | 128 | 331 | 192 |
| EPS in Rs | 7.12 | 68.00 | 32.93 | 28.34 | 20.44 | 32.56 | 28.41 | 39.10 | 32.94 | 34.61 | 27.89 | 72.34 | 41.91 |
Last Updated: August 20, 2025, 5:35 am
Below is a detailed analysis of the quarterly data for Pfizer Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 603.00 Cr.. The value appears strong and on an upward trend. It has increased from 592.00 Cr. (Mar 2025) to 603.00 Cr., marking an increase of 11.00 Cr..
- For Expenses, as of Jun 2025, the value is 393.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 364.00 Cr. (Mar 2025) to 393.00 Cr., marking an increase of 29.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 210.00 Cr.. The value appears to be declining and may need further review. It has decreased from 228.00 Cr. (Mar 2025) to 210.00 Cr., marking a decrease of 18.00 Cr..
- For OPM %, as of Jun 2025, the value is 35.00%. The value appears to be declining and may need further review. It has decreased from 38.00% (Mar 2025) to 35.00%, marking a decrease of 3.00%.
- For Other Income, as of Jun 2025, the value is 67.00 Cr.. The value appears to be declining and may need further review. It has decreased from 217.00 Cr. (Mar 2025) to 67.00 Cr., marking a decrease of 150.00 Cr..
- For Interest, as of Jun 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
- For Depreciation, as of Jun 2025, the value is 14.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 16.00 Cr. (Mar 2025) to 14.00 Cr., marking a decrease of 2.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 260.00 Cr.. The value appears to be declining and may need further review. It has decreased from 426.00 Cr. (Mar 2025) to 260.00 Cr., marking a decrease of 166.00 Cr..
- For Tax %, as of Jun 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 22.00% (Mar 2025) to 26.00%, marking an increase of 4.00%.
- For Net Profit, as of Jun 2025, the value is 192.00 Cr.. The value appears to be declining and may need further review. It has decreased from 331.00 Cr. (Mar 2025) to 192.00 Cr., marking a decrease of 139.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 41.91. The value appears to be declining and may need further review. It has decreased from 72.34 (Mar 2025) to 41.91, marking a decrease of 30.43.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:50 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,112 | 1,853 | 2,012 | 1,966 | 1,969 | 2,082 | 2,152 | 2,239 | 2,611 | 2,425 | 2,193 | 2,281 | 2,375 |
| Expenses | 872 | 1,438 | 1,579 | 1,616 | 1,468 | 1,516 | 1,578 | 1,526 | 1,775 | 1,616 | 1,555 | 1,540 | 1,562 |
| Operating Profit | 239 | 414 | 433 | 350 | 501 | 566 | 574 | 712 | 836 | 809 | 638 | 742 | 813 |
| OPM % | 22% | 22% | 22% | 18% | 25% | 27% | 27% | 32% | 32% | 33% | 29% | 33% | 34% |
| Other Income | 109 | 44 | 97 | 232 | 114 | 167 | 183 | 81 | 63 | 134 | 185 | 344 | 369 |
| Interest | 1 | 2 | 1 | 2 | 1 | 2 | 11 | 15 | 11 | 13 | 15 | 8 | 10 |
| Depreciation | 8 | 250 | 58 | 63 | 66 | 71 | 103 | 109 | 115 | 106 | 62 | 61 | 60 |
| Profit before tax | 340 | 207 | 470 | 517 | 548 | 660 | 642 | 669 | 773 | 824 | 746 | 1,016 | 1,113 |
| Tax % | 35% | 66% | 35% | 35% | 34% | 35% | 21% | 26% | 21% | 24% | 26% | 24% | |
| Net Profit | 221 | 70 | 305 | 337 | 360 | 429 | 509 | 498 | 613 | 624 | 551 | 768 | 839 |
| EPS in Rs | 74.01 | 15.26 | 66.67 | 73.62 | 78.71 | 93.79 | 111.29 | 108.77 | 133.90 | 136.38 | 120.52 | 167.79 | 183.46 |
| Dividend Payout % | 486% | 82% | 22% | 27% | 25% | 24% | 297% | 32% | 26% | 51% | 29% | 98% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -68.33% | 335.71% | 10.49% | 6.82% | 19.17% | 18.65% | -2.16% | 23.09% | 1.79% | -11.70% | 39.38% |
| Change in YoY Net Profit Growth (%) | 0.00% | 404.04% | -325.22% | -3.67% | 12.34% | -0.52% | -20.81% | 25.25% | -21.30% | -13.49% | 51.08% |
Pfizer Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 1% |
| 3 Years: | -4% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 5% |
| 3 Years: | 2% |
| TTM: | 12% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 2% |
| 3 Years: | 6% |
| 1 Year: | -16% |
| Return on Equity | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 18% |
| 3 Years: | 17% |
| Last Year: | 16% |
Last Updated: September 5, 2025, 12:15 pm
Balance Sheet
Last Updated: December 10, 2025, 3:13 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 30 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 |
| Reserves | 629 | 1,927 | 2,118 | 2,373 | 2,637 | 2,966 | 3,350 | 2,347 | 2,819 | 3,162 | 3,550 | 4,172 | 3,803 |
| Borrowings | -0 | 2 | 2 | 2 | 2 | 2 | 2 | 63 | 39 | 41 | 40 | 41 | 43 |
| Other Liabilities | 318 | 638 | 722 | 840 | 1,004 | 926 | 1,007 | 810 | 997 | 752 | 593 | 653 | 714 |
| Total Liabilities | 977 | 2,614 | 2,888 | 3,261 | 3,690 | 3,940 | 4,405 | 3,266 | 3,901 | 4,001 | 4,229 | 4,911 | 4,606 |
| Fixed Assets | 20 | 944 | 925 | 902 | 950 | 886 | 973 | 894 | 869 | 749 | 713 | 724 | 701 |
| CWIP | 3 | 13 | 3 | 15 | 1 | -0 | 1 | 3 | 1 | 8 | 0 | 8 | 8 |
| Investments | 44 | 43 | 37 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Other Assets | 909 | 1,614 | 1,923 | 2,343 | 2,739 | 3,054 | 3,432 | 2,369 | 3,030 | 3,244 | 3,516 | 4,180 | 3,897 |
| Total Assets | 977 | 2,614 | 2,888 | 3,261 | 3,690 | 3,940 | 4,405 | 3,266 | 3,901 | 4,001 | 4,229 | 4,911 | 4,606 |
Below is a detailed analysis of the balance sheet data for Pfizer Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 46.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 46.00 Cr..
- For Reserves, as of Sep 2025, the value is 3,803.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4,172.00 Cr. (Mar 2025) to 3,803.00 Cr., marking a decrease of 369.00 Cr..
- For Borrowings, as of Sep 2025, the value is 43.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 41.00 Cr. (Mar 2025) to 43.00 Cr., marking an increase of 2.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 714.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 653.00 Cr. (Mar 2025) to 714.00 Cr., marking an increase of 61.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 4,606.00 Cr.. The value appears to be improving (decreasing). It has decreased from 4,911.00 Cr. (Mar 2025) to 4,606.00 Cr., marking a decrease of 305.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 701.00 Cr.. The value appears to be declining and may need further review. It has decreased from 724.00 Cr. (Mar 2025) to 701.00 Cr., marking a decrease of 23.00 Cr..
- For CWIP, as of Sep 2025, the value is 8.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 8.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 3,897.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4,180.00 Cr. (Mar 2025) to 3,897.00 Cr., marking a decrease of 283.00 Cr..
- For Total Assets, as of Sep 2025, the value is 4,606.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4,911.00 Cr. (Mar 2025) to 4,606.00 Cr., marking a decrease of 305.00 Cr..
Notably, the Reserves (3,803.00 Cr.) exceed the Borrowings (43.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 239.00 | 412.00 | 431.00 | 348.00 | 499.00 | 564.00 | 572.00 | 649.00 | 797.00 | 768.00 | 598.00 | 701.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 57 | 32 | 26 | 20 | 29 | 30 | 29 | 18 | 20 | 23 | 31 | 31 |
| Inventory Days | 148 | 191 | 167 | 148 | 147 | 189 | 198 | 199 | 173 | 175 | 200 | 214 |
| Days Payable | 156 | 165 | 157 | 178 | 245 | 213 | 197 | 130 | 102 | 91 | 77 | 68 |
| Cash Conversion Cycle | 49 | 58 | 36 | -10 | -69 | 6 | 31 | 87 | 91 | 107 | 154 | 177 |
| Working Capital Days | 25 | 7 | -9 | -47 | -57 | -16 | -8 | 3 | -14 | -4 | 24 | 23 |
| ROCE % | 29% | 24% | 22% | 17% | 21% | 23% | 20% | 23% | 29% | 26% | 22% | 22% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Nippon India Small Cap Fund | 1,206,103 | 0.88 | 600.04 | 947,910 | 2025-12-08 07:42:13 | 27.24% |
| Quant Small Cap Fund | 914,527 | 1.51 | 454.98 | 875,027 | 2025-12-15 09:05:47 | 4.51% |
| Nippon India Multi Cap Fund | 362,848 | 0.36 | 180.52 | 362,848 | 2025-04-22 15:56:54 | 0% |
| ICICI Prudential Value Fund | 328,943 | 0.27 | 163.65 | N/A | N/A | N/A |
| Nippon India Pharma Fund | 318,249 | 1.87 | 158.33 | 293,249 | 2025-12-08 04:19:42 | 8.53% |
| ICICI Prudential Smallcap Fund | 288,602 | 1.7 | 143.58 | 230,129 | 2025-12-14 01:36:52 | 25.41% |
| UTI Mid Cap Fund | 246,276 | 1.02 | 122.52 | N/A | N/A | N/A |
| DSP Healthcare Fund | 200,644 | 3.14 | 99.82 | N/A | N/A | N/A |
| ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund | 180,970 | 1.39 | 90.03 | N/A | N/A | N/A |
| DSP Large & Mid Cap Fund | 178,101 | 0.51 | 88.61 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 136.46 | 120.51 | 128.50 | 133.89 | 108.77 |
| Diluted EPS (Rs.) | 167.79 | 120.51 | 136.38 | 133.89 | 108.77 |
| Cash EPS (Rs.) | 181.07 | 134.12 | 159.44 | 159.03 | 132.68 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 921.84 | 785.91 | 701.05 | 626.10 | 523.07 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 921.84 | 785.91 | 701.05 | 626.10 | 523.07 |
| Dividend / Share (Rs.) | 165.00 | 35.00 | 70.00 | 35.00 | 35.00 |
| Revenue From Operations / Share (Rs.) | 498.65 | 479.38 | 530.00 | 570.71 | 489.30 |
| PBDIT / Share (Rs.) | 199.45 | 178.32 | 198.89 | 196.37 | 173.38 |
| PBIT / Share (Rs.) | 186.16 | 164.71 | 175.82 | 171.23 | 149.47 |
| PBT / Share (Rs.) | 222.10 | 163.07 | 180.11 | 168.94 | 146.17 |
| Net Profit / Share (Rs.) | 167.78 | 120.51 | 136.38 | 133.89 | 108.77 |
| PBDIT Margin (%) | 39.99 | 37.19 | 37.52 | 34.40 | 35.43 |
| PBIT Margin (%) | 37.33 | 34.35 | 33.17 | 30.00 | 30.54 |
| PBT Margin (%) | 44.53 | 34.01 | 33.98 | 29.60 | 29.87 |
| Net Profit Margin (%) | 33.64 | 25.13 | 25.73 | 23.46 | 22.22 |
| Return on Networth / Equity (%) | 18.20 | 15.33 | 19.45 | 21.38 | 20.79 |
| Return on Capital Employeed (%) | 19.61 | 20.46 | 24.05 | 25.70 | 27.44 |
| Return On Assets (%) | 15.62 | 13.03 | 15.59 | 15.70 | 15.23 |
| Asset Turnover Ratio (%) | 0.49 | 0.53 | 0.61 | 0.72 | 0.58 |
| Current Ratio (X) | 6.17 | 5.07 | 3.84 | 2.81 | 2.49 |
| Quick Ratio (X) | 5.33 | 4.27 | 3.21 | 2.28 | 1.92 |
| Inventory Turnover Ratio (X) | 0.59 | 0.78 | 0.79 | 0.80 | 0.77 |
| Dividend Payout Ratio (NP) (%) | 20.86 | 33.19 | 47.65 | 26.13 | 303.38 |
| Dividend Payout Ratio (CP) (%) | 19.33 | 29.82 | 40.76 | 22.00 | 248.70 |
| Earning Retention Ratio (%) | 79.14 | 66.81 | 52.35 | 73.87 | -203.38 |
| Cash Earning Retention Ratio (%) | 80.67 | 70.18 | 59.24 | 78.00 | -148.70 |
| Interest Coverage Ratio (X) | 108.50 | 52.94 | 67.95 | 85.64 | 52.50 |
| Interest Coverage Ratio (Post Tax) (X) | 71.72 | 36.26 | 45.13 | 59.39 | 33.93 |
| Enterprise Value (Cr.) | 15519.59 | 17140.82 | 13990.32 | 18276.37 | 19572.81 |
| EV / Net Operating Revenue (X) | 6.80 | 7.82 | 5.77 | 7.00 | 8.74 |
| EV / EBITDA (X) | 17.01 | 21.01 | 15.38 | 20.34 | 24.67 |
| MarketCap / Net Operating Revenue (X) | 8.03 | 8.75 | 6.54 | 7.62 | 9.24 |
| Retention Ratios (%) | 79.13 | 66.80 | 52.34 | 73.86 | -203.38 |
| Price / BV (X) | 4.34 | 5.34 | 4.94 | 6.95 | 8.64 |
| Price / Net Operating Revenue (X) | 8.03 | 8.75 | 6.54 | 7.62 | 9.24 |
| EarningsYield | 0.04 | 0.02 | 0.03 | 0.03 | 0.02 |
After reviewing the key financial ratios for Pfizer Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 136.46. This value is within the healthy range. It has increased from 120.51 (Mar 24) to 136.46, marking an increase of 15.95.
- For Diluted EPS (Rs.), as of Mar 25, the value is 167.79. This value is within the healthy range. It has increased from 120.51 (Mar 24) to 167.79, marking an increase of 47.28.
- For Cash EPS (Rs.), as of Mar 25, the value is 181.07. This value is within the healthy range. It has increased from 134.12 (Mar 24) to 181.07, marking an increase of 46.95.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 921.84. It has increased from 785.91 (Mar 24) to 921.84, marking an increase of 135.93.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 921.84. It has increased from 785.91 (Mar 24) to 921.84, marking an increase of 135.93.
- For Dividend / Share (Rs.), as of Mar 25, the value is 165.00. This value exceeds the healthy maximum of 3. It has increased from 35.00 (Mar 24) to 165.00, marking an increase of 130.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 498.65. It has increased from 479.38 (Mar 24) to 498.65, marking an increase of 19.27.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 199.45. This value is within the healthy range. It has increased from 178.32 (Mar 24) to 199.45, marking an increase of 21.13.
- For PBIT / Share (Rs.), as of Mar 25, the value is 186.16. This value is within the healthy range. It has increased from 164.71 (Mar 24) to 186.16, marking an increase of 21.45.
- For PBT / Share (Rs.), as of Mar 25, the value is 222.10. This value is within the healthy range. It has increased from 163.07 (Mar 24) to 222.10, marking an increase of 59.03.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 167.78. This value is within the healthy range. It has increased from 120.51 (Mar 24) to 167.78, marking an increase of 47.27.
- For PBDIT Margin (%), as of Mar 25, the value is 39.99. This value is within the healthy range. It has increased from 37.19 (Mar 24) to 39.99, marking an increase of 2.80.
- For PBIT Margin (%), as of Mar 25, the value is 37.33. This value exceeds the healthy maximum of 20. It has increased from 34.35 (Mar 24) to 37.33, marking an increase of 2.98.
- For PBT Margin (%), as of Mar 25, the value is 44.53. This value is within the healthy range. It has increased from 34.01 (Mar 24) to 44.53, marking an increase of 10.52.
- For Net Profit Margin (%), as of Mar 25, the value is 33.64. This value exceeds the healthy maximum of 10. It has increased from 25.13 (Mar 24) to 33.64, marking an increase of 8.51.
- For Return on Networth / Equity (%), as of Mar 25, the value is 18.20. This value is within the healthy range. It has increased from 15.33 (Mar 24) to 18.20, marking an increase of 2.87.
- For Return on Capital Employeed (%), as of Mar 25, the value is 19.61. This value is within the healthy range. It has decreased from 20.46 (Mar 24) to 19.61, marking a decrease of 0.85.
- For Return On Assets (%), as of Mar 25, the value is 15.62. This value is within the healthy range. It has increased from 13.03 (Mar 24) to 15.62, marking an increase of 2.59.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.49. It has decreased from 0.53 (Mar 24) to 0.49, marking a decrease of 0.04.
- For Current Ratio (X), as of Mar 25, the value is 6.17. This value exceeds the healthy maximum of 3. It has increased from 5.07 (Mar 24) to 6.17, marking an increase of 1.10.
- For Quick Ratio (X), as of Mar 25, the value is 5.33. This value exceeds the healthy maximum of 2. It has increased from 4.27 (Mar 24) to 5.33, marking an increase of 1.06.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.59. This value is below the healthy minimum of 4. It has decreased from 0.78 (Mar 24) to 0.59, marking a decrease of 0.19.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 20.86. This value is within the healthy range. It has decreased from 33.19 (Mar 24) to 20.86, marking a decrease of 12.33.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 19.33. This value is below the healthy minimum of 20. It has decreased from 29.82 (Mar 24) to 19.33, marking a decrease of 10.49.
- For Earning Retention Ratio (%), as of Mar 25, the value is 79.14. This value exceeds the healthy maximum of 70. It has increased from 66.81 (Mar 24) to 79.14, marking an increase of 12.33.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 80.67. This value exceeds the healthy maximum of 70. It has increased from 70.18 (Mar 24) to 80.67, marking an increase of 10.49.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 108.50. This value is within the healthy range. It has increased from 52.94 (Mar 24) to 108.50, marking an increase of 55.56.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 71.72. This value is within the healthy range. It has increased from 36.26 (Mar 24) to 71.72, marking an increase of 35.46.
- For Enterprise Value (Cr.), as of Mar 25, the value is 15,519.59. It has decreased from 17,140.82 (Mar 24) to 15,519.59, marking a decrease of 1,621.23.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 6.80. This value exceeds the healthy maximum of 3. It has decreased from 7.82 (Mar 24) to 6.80, marking a decrease of 1.02.
- For EV / EBITDA (X), as of Mar 25, the value is 17.01. This value exceeds the healthy maximum of 15. It has decreased from 21.01 (Mar 24) to 17.01, marking a decrease of 4.00.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 8.03. This value exceeds the healthy maximum of 3. It has decreased from 8.75 (Mar 24) to 8.03, marking a decrease of 0.72.
- For Retention Ratios (%), as of Mar 25, the value is 79.13. This value exceeds the healthy maximum of 70. It has increased from 66.80 (Mar 24) to 79.13, marking an increase of 12.33.
- For Price / BV (X), as of Mar 25, the value is 4.34. This value exceeds the healthy maximum of 3. It has decreased from 5.34 (Mar 24) to 4.34, marking a decrease of 1.00.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 8.03. This value exceeds the healthy maximum of 3. It has decreased from 8.75 (Mar 24) to 8.03, marking a decrease of 0.72.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.02 (Mar 24) to 0.04, marking an increase of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Pfizer Ltd:
- Net Profit Margin: 33.64%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 19.61% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 18.2% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 71.72
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 5.33
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 32.8 (Industry average Stock P/E: 51.48)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 33.64%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | The Capital, 1802 / 1901, 18th Floor, Mumbai Maharashtra 400051 | contactus.india@pfizer.com http://www.pfizerltd.co.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Pradip Shah | Chairman & Ind.Director |
| Ms. Meenakshi Nevatia | Managing Director |
| Mr. P Rengan | Executive Director - Operations |
| Mr. Amit Agarwal | Executive Director & CFO |
| Ms. Meena Ganesh | Independent Director |
| Mr. Lakshmanan Krishnakumar | Independent Director |
| Ms. Sonia Singh | Independent Director |
FAQ
What is the intrinsic value of Pfizer Ltd?
Pfizer Ltd's intrinsic value (as of 17 December 2025) is 3644.10 which is 27.95% lower the current market price of 5,058.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 23,156 Cr. market cap, FY2025-2026 high/low of 5,993/3,701, reserves of ₹3,803 Cr, and liabilities of 4,606 Cr.
What is the Market Cap of Pfizer Ltd?
The Market Cap of Pfizer Ltd is 23,156 Cr..
What is the current Stock Price of Pfizer Ltd as on 17 December 2025?
The current stock price of Pfizer Ltd as on 17 December 2025 is 5,058.
What is the High / Low of Pfizer Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Pfizer Ltd stocks is 5,993/3,701.
What is the Stock P/E of Pfizer Ltd?
The Stock P/E of Pfizer Ltd is 32.8.
What is the Book Value of Pfizer Ltd?
The Book Value of Pfizer Ltd is 841.
What is the Dividend Yield of Pfizer Ltd?
The Dividend Yield of Pfizer Ltd is 0.69 %.
What is the ROCE of Pfizer Ltd?
The ROCE of Pfizer Ltd is 21.6 %.
What is the ROE of Pfizer Ltd?
The ROE of Pfizer Ltd is 16.4 %.
What is the Face Value of Pfizer Ltd?
The Face Value of Pfizer Ltd is 10.0.